title: A potential role of cyclic GMP in the regulation of lordosis behavior of female rats.
abstract: Nitric oxide (NO) has been suggested to play a crucial role in the regulation of lordosis behavior via stimulation of guanylyl cyclase to synthesize cyclic GMP. Whalen and Lauber (1986, Neurosci. Biobehav. Rev. 10, 47-53) hypothesized that hormones and pharmacological agents known to facilitate lordosis in estrogen-primed rodents act through cyclic GMP. The compound 1H-[1,2, 4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) has been shown to selectively inhibit NO-stimulated cyclic GMP production. In the present study, we investigated the effects of ODQ on lordosis behavior. Female rats were implanted with a guide cannula aimed at the lateral or third ventricles by stereotaxic surgery, and their ovaries were bilaterally removed. Five days later, animals were injected subcutaneously with 2 microg estradiol benzoate at 48 and 24 hr, and 200 microg progesterone 4 hr before behavioral testing. ODQ or vehicle (1 microl) was administered at the time of progesterone treatment or 20 min before lordosis testing. ODQ significantly decreased lordosis quotients and the quality of lordosis at both intervals of drug infusion. Locomotor activities, measured by line crossing and rearing, were not affected by ODQ. ODQ also inhibited cyclic GMP accumulation in response to NMDA stimulation in hypothalamic and cerebellar slices in vitro. We conclude that cyclic GMP produced by NO generation is an important modulator of female rat sexual behavior.
authors.affiliation: Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
authors.forename: H P
authors.initials: HP
authors.lastname: Chu
authors.forename: A M
authors.initials: AM
authors.lastname: Etgen
mesh_terms: D000818:Animals; D002531:Cerebellum / Q000187:drug effects / Q000502:physiology; D002552:Cerebral Ventricles; D006152:Cyclic GMP / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D007031:Hypothalamus / Q000187:drug effects / Q000502:physiology; D007276:Injections, Intraventricular; D009569:Nitric Oxide / Q000378:metabolism; D009924:Organ Culture Techniques; D010069:Oxadiazoles / Q000494:pharmacology; D011187:Posture / Q000502:physiology*; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley / Q000502:physiology*; D012726:Sexual Behavior, Animal / Q000187:drug effects / Q000502:physiology*
chemical_list: C095284:1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one; D004791:Enzyme Inhibitors; D010069:Oxadiazoles; D011810:Quinoxalines; D009569:Nitric Oxide; D006152:Cyclic GMP